Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Progyny Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Progyny hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.7%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$0.64
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Oct 18

Progyny Stock Should Deliver Superior Returns For Investors

Aug 05

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Jul 27

At US$31.63, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 08

Progyny: Solving Infertility Problem

Jul 05

Progyny Stock: A Hidden Gem Tackling Infertility

May 31

Investors Will Want Progyny's (NASDAQ:PGNY) Growth In ROCE To Persist

Apr 18

At US$50.90, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?

Mar 31

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PGNY in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PGNY gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Progyny Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von PGNY im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (PGNY)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Healthcare)	1.7%
Analystenprognose in 3 Jahren (PGNY)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PGNY im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PGNY im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PGNY, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PGNY keine Ausschüttungen gemeldet hat.

Progyny Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Price target decreased by 7.1% to US$43.40

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Progyny, Inc. to Report Q1, 2024 Results on May 09, 2024

Progyny, Inc., Annual General Meeting, May 23, 2024

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Executive Chairman exercised options and sold US$2.4m worth of stock

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Progyny: Long-Term Thesis Still Intact

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. Announces Executive Appointments

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Executive Chairman exercised options and sold US$5.5m worth of stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Progyny, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Consensus EPS estimates increase by 28%

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Progyny, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive Chairman exercised options and sold US$4.0m worth of stock

Executive Chairman exercised options and sold US$714k worth of stock

Executive Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$54k worth of stock

Consensus EPS estimates increase by 54%

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Raises Financial Guidance for the Full Year Ending December 31, 2023

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

CEO & Director exercised options and sold US$318k worth of stock

Consensus EPS estimates fall by 17%

Executive Chairman exercised options and sold US$4.0m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Investor sentiment deteriorates as stock falls 16%

Executive Chairman exercised options and sold US$3.5m worth of stock

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Price target decreased to US$48.57

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Chief Financial Officer recently sold US$543k worth of stock

Independent Director notifies of intention to sell stock

Price target decreased to US$55.57

CEO & Director notifies of intention to sell stock

Consensus EPS estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Progyny, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Executive Chairman exercised options and sold US$87k worth of stock

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

CEO & Director recently sold US$212k worth of stock

Executive Chairman exercised options and sold US$2.4m worth of stock

Executive Chairman exercised options and sold US$1.6m worth of stock

Progyny, Inc. Appoints Lloyd H. Dean as Class I Director

Consensus EPS estimates increase by 21%

Executive Chairman notifies of intention to sell stock

Progyny, Inc. Provides Earnings Outlook for the Third Quarter and Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Progyny Stock Should Deliver Superior Returns For Investors

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Progyny, Inc. to Report Q2, 2022 Results on Aug 04, 2022